Efficacy and safety of apremilast for patients with plaque psoriasis
ZHU Enyi
ZHI Cuisong
GAN Yichuan
YE Hui
LUO Quan
ZHANG Sanquan
YE Qianru
LI Wei
Abstract：Objective To assess the efficacy and safety of apremilast in the treatment of plaque psoriasis.Methods Fifty patients with plaque psoriasis were enrolled and categorized into mild,moderate,and severe groups based on disease severity.They received 12 weeks of treatment with apremilast.The psoriasis area and severity index(PASI)scores,as well as PASI50,PA-SI75,and PASI90,were recorded at weeks 0,4,8,and 12.Additionally,the incidence and se-verity of adverse events were recorded.Results Fifty patients included 12 mild cases,33 moder-ate cases,and 5 severe cases.At weeks 4,8,and 12,the PASI scores for mild(0.60±0.40,0.34±0.29,0.27±0.26),moderate(2.43±1.17,1.55±0.94,1.06±0.83),and severe(7.04±0.94,5.26±1.48,4.18±1.55)groups significantly decreased from baseline.The PA-SI50,PASI75,and PASI90 were highest in the mild group(PASI50:75%,100%,100%;PA-SI75:42%,75%,75%;PASI90:0,17%,50%),while they were lowest in the severe group.Fifty-six percent of patients reported at least one adverse event during the 12-week period,with the most common being diarrhea(30%),nausea(12%),and muscle pain(6%).Few patients ex-perienced depression,headache,stomachache,or toothache.No serious adverse events occurred.Conclusions Apremilast demonstrates good efficacy for mild to moderate plaque psoriasis.Diar-rhea is the most commonly reported adverse event and is generally well tolerated.
Keywords：plaque psoriasisapremilast
Publication Date：2025-12-28
Online Publishing Date：2026-01-13(First online date of this platform, not the publication date of the document)
Pages：6( 846-851 )